retatrutide companies Company linked to raid on illicit weight-loss drug facility still selling unlicensed drugs | Consumer affairs Retatrutide for weight loss: Study

Bridging the gap between clinical potential and real-world impact enables stakeholders to decode the complex interplay of these forces and rethink what it truly takes to keep patients on the path to sustained outcomes

A more mindful, wellness-forward approach to GLP-1 use

Tirzepatide and chest pain: Learn whether this diabetes medication causes chest discomfort, how to distinguish cardiac symptoms from side effects, and when to seek immediate medical attention while on therapy.

Ozempic alternatives in the GLP-1 family offer effective weight loss pathways

NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioid use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD 6.61 (7.95 to 5.26))